What caused Roche's Hunt­ing­ton's drug tomin­ersen to hit the skids in late-stage test? It's com­pli­cat­ed, an­a­lysts say

Just last month, Roche hit the pause but­ton on a Phase III test for Hunt­ing­ton’s hope­ful tomin­ersen af­ter a da­ta com­mit­tee ques­tioned its risk/ben­e­fit pro­file. Now, the drug­mak­er is con­duct­ing an au­top­sy to see what went wrong, but an­swers are in short sup­ply.

On Tues­day, Roche pre­sent­ed fol­low-up da­ta from tomin­ersen that sought to pro­vide some clue be­hind why the drug­mak­er halt­ed its Phase III test. The an­swer? It’s com­pli­cat­ed, Stifel an­a­lysts wrote in a note to clients Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.